Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
ID: 331840Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/331840

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-136.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is inviting applications for the R33 Exploratory/Developmental Grants Phase II funding opportunity, aimed at early-stage testing of pharmacologic and device-based interventions for mental disorders. This initiative seeks to support studies that validate molecular or circuit-based targets and assess their impact on clinical outcomes for conditions such as schizophrenia, depression, and anxiety, with a focus on innovative interventions that have not yet received FDA approval. The total funding commitment for this opportunity is $27 million, with a proposal deadline of February 15, 2024. Interested applicants can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PAR-21-136-Full-Announcement.html
    PAR-21-136.html
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is soliciting applications for the R33 Exploratory/Developmental Grants Phase II funding opportunity, aimed at early-stage testing of pharmacologic and device-based interventions for mental disorders. This initiative focuses on studies to validate molecular or circuit-based targets and determine their effect on clinical outcomes in conditions such as schizophrenia, depression, and anxiety. The funding supports innovative interventions that are not yet FDA approved and encourages collaboration between academic and industry researchers. Key requirements include demonstrating preliminary data on target engagement and ensuring all involved interventions have passed Phase I safety studies. The proposal deadline is February 15, 2024, and the anticipated number of awards includes a total funding commitment of $27 million for related projects. The document outlines eligibility criteria, application requirements, evaluation metrics, and guidance on data sharing via the National Data Archive, reflecting NIH’s commitment to advancing research on mental health interventions.
    Similar Opportunities
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)" aimed at advancing the development of innovative brain stimulation devices for mental health treatment. This initiative seeks applications that either create novel devices or significantly enhance existing FDA-approved devices through hardware and software improvements, focusing on increased precision and effectiveness in treatment. The funding underscores the importance of multidisciplinary collaboration in neuroscience and engineering, with an emphasis on innovative approaches rather than incremental changes. Interested applicants can find more information and submit proposals by January 7, 2028, with no budget cap but a maximum project duration of five years. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-287.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at encouraging research into high-confidence risk factors associated with complex brain disorders such as schizophrenia, bipolar disorder, and major depression. This initiative supports exploratory developmental research (R21) to identify molecular, cellular, and circuit mechanisms involved in these disorders, utilizing diverse experimental paradigms without the necessity for prior feasibility data. The funding amount is capped at $275,000 over two years, with a maximum of $200,000 per year, and eligible applicants include a wide range of educational institutions, nonprofits, and for-profit organizations. Interested parties can find more information and application details at the NIH website, with the application deadline set for September 7, 2026.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)." This grant aims to support innovative research utilizing invasive neural recording methods to explore the neural circuitry associated with mental health disorders, focusing on high-risk applications that address significant gaps in knowledge regarding complex moods and cognitive behaviors. The initiative seeks to bridge basic neuroscience with applied mental health interventions, encouraging diverse research teams to utilize advanced methodologies. The estimated funding amount is capped at $200,000, with applications due by January 7, 2028. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-291.html.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed) to support innovative and exploratory research projects in neuroscience. This grant program is designed for early-stage projects that align with the missions of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Mental Health (NIMH), focusing on studies that assess the feasibility of novel investigations with the potential for significant breakthroughs in neuroscience. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and foreign entities, with funding available up to $275,000 over two years. The application period opens on January 16, 2025, with anticipated awards by July 2025; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is inviting applications for the Biobehavioral Research Awards for Innovative New Scientists (BRAINS), aimed at supporting early-stage investigators in launching innovative research focused on mental disorders. This program seeks to fund high-risk, high-reward projects that may not have the preliminary data typically required for traditional funding, with an emphasis on advancing understanding and treatment of mental health issues. Eligible applicants include tenure-track faculty designated as Early Stage Investigators by NIH, and the grant provides up to $500,000 per year for a maximum of five years, with a total of approximately $3 million allocated annually for 6-8 awards. Interested parties can find more information and apply by June 20, 2025, and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Research Project Grants (R01) aimed at the development of screening assays for drug candidates targeting psychiatric disorders. The primary objectives of this initiative are to stimulate research in the discovery and development of novel small molecules that can potentially treat mental illnesses, as well as to validate compounds that demonstrate desired biological activity through rigorous screening processes. This funding is crucial for advancing therapeutic options for conditions such as depression, schizophrenia, and PTSD, and it encourages applicants to align their proposals with the National Institute of Mental Health (NIMH) priorities. Interested applicants must submit their proposals by May 7, 2026, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG)" aimed at advancing the treatment of mental disorders and alcohol use disorder through innovative drug and device therapies. This cooperative agreement encourages applications from partnerships between academia and industry, focusing on the discovery, preclinical development, and proof of concept testing of new therapeutic interventions, including pharmacologic and neuromodulatory tools. The initiative is crucial for fostering collaboration to expedite the development of effective treatments for pressing mental health issues, with applications due by February 24, 2025. Interested applicants can find more information and guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)." This initiative aims to support invasive neural recording studies that investigate the neural circuitry and dynamics associated with mental health disorders, encouraging researchers to address specific questions with high translational potential. The program emphasizes the importance of innovative collaborations in neuroscience and engineering to enhance understanding and therapeutic approaches for mental health challenges. Applications will open on January 5, 2025, with a project duration of up to five years and no budget limits. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-290.html.